Unstable Angina Clinical Presentation

  • Author: Walter A Tan, MD, MS; Chief Editor: Eric H Yang, MD   more...
 
Updated: Dec 7, 2011
 

History

Patients with unstable angina represent a heterogeneous population. Therefore, the clinician must obtain a focused history of the patient's symptoms and coronary risk factors and immediately review the ECG to develop an early risk stratification. (See Prognosis.)

Initially obtain a history to determine whether any evidence of angina is present, and then aim to identify whether it is stable or unstable.

Next

Physical Examination

The physical examination is usually not as sensitive or specific for unstable angina as history or diagnostic tests. An unremarkable physical examination is not uncommon. Perform a quick assessment of patients' vital signs, and perform a cardiac examination. Specific diagnoses that must be explicitly considered are the following:

  • Aortic dissection
  • Leaking or ruptured thoracic aneurysm
  • Pericarditis with tamponade
  • Pulmonary embolism
  • Pneumothorax

Unstable angina differs from stable angina in that the discomfort is usually more intense and easily provoked, and ST-segment depression or elevation on ECG may occur. Otherwise, the manifestations of unstable angina are similar to those of other conditions of myocardial ischemia, such as chronic stable angina and myocardial infarction.

Angina can take many forms, and inquiry should be directed at eliciting not only chest pain but also any discomfort and its frequency, location, radiation pattern, and precipitating and alleviating factors. Ischemic pain can manifest as heaviness, tightness, aching, fullness, or burning of the chest, epigastrium, and/or arm or forearm (usually the left). These sensations less typically involve the lower jaw, neck, or shoulder. Important associated symptoms may be dyspnea, generalized fatigue, diaphoresis, nausea and vomiting, flulike symptoms, and, less commonly, lightheadedness or abdominal pain.

Elderly and female patients are more likely to present with atypical signs and symptoms.

Increased autonomic activity may manifest as diaphoresis or tachycardia, and bradycardia may result from vagal stimulation from inferior wall myocardial ischemia.

A large area of myocardial jeopardy may manifest as signs of transient myocardial dysfunction and typically signifies a higher-risk situation. Signs include the following:

  • Systolic blood pressure less than 100 mm Hg or overt hypotension
  • Elevated jugular venous pressure
  • Dyskinetic apex
  • Reverse splitting of the second heart sound
  • Presence of a third or fourth heart sound
  • New or worsening apical systolic murmur due to papillary muscle dysfunction
  • Rales or crackles

Patients with acute coronary syndrome may present with a chief symptom of pain or discomfort in the chest or left arm, particularly if it reproduces previously documented angina.

Findings indicative of peripheral arterial occlusive disease or prior stroke increase the likelihood of associated coronary artery disease and are as follows:

  • Carotid bruit
  • Supraclavicular or femoral bruits
  • Diminished peripheral pulses or blood pressure

Any sign of congestive heart failure, including isolated tachycardia, particularly in physiologically vulnerable populations (eg, very elderly patients), should trigger expeditious workup, treatment, or consultation with a cardiologist. Such patients can deteriorate rapidly.

The number and diversity of clinical conditions that cause the transient myocardial ischemia of unstable angina along with its varying intensity and frequency of pain have made classification within this disorder difficult.

Previous
Next

Braunwald Classification

The Braunwald classification is conceptually useful because it factors in the clinical presentation (new or progressive vs rest angina), context (primary, secondary, or post–myocardial infarction), and intensity of antianginal therapy.

Table 4. Braunwald Classification of Unstable Angina (Open Table in a new window)

CharacteristicClass/CategoryDetails
SeverityISymptoms with exertion
IISubacute symptoms at rest (2-30 d prior)
IIIAcute symptoms at rest (within prior 48 h)
Clinical precipitating factorASecondary
BPrimary
CPostinfarction
Therapy during symptoms1No treatment
2Usual angina therapy
3Maximal therapy

Patients in class I have new or accelerated exertional angina, whereas those in class II have subacute (>48 h since last pain) or class III acute (< 48 h since last pain) rest angina. The clinical circumstances associated with unstable angina are categorized as (A) secondary (anemia, fever, hypoxia), (B) primary, or (C) postinfarction (< 2 wk after infarction). Intensity of antianginal therapy is subclassified as (1) no treatment, (2) usual oral therapy, and (3) intense therapy, such as intravenous nitroglycerin.

Previous
Next

Canadian Cardiovascular Society Grading System

The Canadian Cardiovascular Society Grading System for effort-related angina is widely used since it is a simple and practical classification that is often used to describe symptom severity. The grading system is as follows:

  • Grade I - Angina with strenuous, rapid, or prolonged exertion (Ordinary physical activity such as climbing stairs does not provoke angina.)
  • Grade II - Slight limitation of ordinary activity (Angina occurs with postprandial, uphill, or rapid walking; when walking more than 2 blocks of level ground or climbing more than 1 flight of stairs; during emotional stress; or in the early hours after awakening.)
  • Grade III - Marked limitation of ordinary activity (Angina occurs with walking 1-2 blocks or climbing a flight of stairs at a normal pace.)
  • Grade IV - Inability to carry on any physical activity without discomfort (Rest pain occurs.)
Previous
Next

Acute Coronary Syndrome Risk Assessment

Estimation of the likelihood of acute coronary syndrome is a complex, multivariable problem that cannot be fully specified in the below list. The following is meant to illustrate major relationships rather than to offer rigid algorithms.

High likelihood of acute coronary syndrome includes any of the following features:

  • History of prior myocardial infarction, sudden death, or other known history of coronary artery disease
  • Chest or left arm pain consistent with prior documented angina
  • Transient hemodynamic or electrocardiographic changes during pain
  • ST-segment elevation or depression 1 mm or more
  • Marked symmetrical T-wave inversion in multiple precordial leads

Intermediate likelihood of acute coronary syndrome includes the absence of high-likelihood features but the presence of 1 of these risk characteristics:

  • Age older than 70 years
  • Male sex
  • Diabetes mellitus
  • Extracardiac vascular disease (peripheral, brachiocephalic, or renal artery atherosclerosis)
  • ST depression 0.05-1 mm
  • T-wave inversion 1 mm or greater in leads with dominant R waves

Low likelihood of acute coronary syndrome includes the absence of high- or intermediate-likelihood features and the presence of any of the following:

  • Chest pain classified as probably not angina
  • Chest discomfort reproduced by palpation
  • T-wave flattening or inversion of less than 1 mm in leads with dominant R waves
  • Normal electrocardiographic findings
Previous
Next

Thrombolysis in Myocardial Infarction Risk Score

The TIMI Risk Score for unstable angina/NSTEMI is currently the best-validated prognostic instrument that is simple enough to use in an emergency department setting. The gradient of myocardial infarction, severe recurrent ischemia, or death is somewhat proportionate to the TIMI Risk Score (see the graphs below), although an adverse prognosis appears to be mitigated by the use of newer antithrombotic strategies.

Thrombolysis in Myocardial Infarction (TIMI) Risk Thrombolysis in Myocardial Infarction (TIMI) Risk Score correlates with major adverse outcome and the effect of therapy with low molecular weight heparin.

The inflection point for myocardial infarction or death starts at a TIMI Risk Score of 3. Therefore, patients with a score of 3-7 should be considered for use of intravenous glycoprotein IIb/IIIa agents, heparin (low molecular weight or unfractionated), and early cardiac catheterization (see Treatment and Management).

The presence of any of the following variables constitutes 1 point, with the sum constituting the patient risk score on a scale of 0-7:

  • Aged 65 years or older
  • Use of aspirin in the last 7 days
  • Known coronary stenosis of 50% or greater
  • Elevated serum cardiac markers
  • At least 3 risk factors for coronary artery disease (including diabetes mellitus, active smoker, family history of coronary artery disease, hypertension, hypercholesterolemia)
  • Severe anginal symptoms (2 or more anginal events in the last 24 h)
  • ST deviation on ECG
Previous
 
 
Contributor Information and Disclosures
Author

Walter A Tan, MD, MS  Associate Professor of Medicine, Clinical Associate Professor of Surgery, Director of Stroke Interventions, Associate Director of Cardiac Catheterization, Department of Cardiovascular Sciences, Brody School of Medicine, East Carolina University

Walter A Tan, MD, MS is a member of the following medical societies: American Association for the Advancement of Science, American College of Cardiology, American Heart Association, American Stroke Association, National Stroke Association, Society for Vascular Medicine and Biology, and Society of Interventional Radiology

Disclosure: Gilead Honoraria Other

Coauthor(s)

David J Moliterno, MD  Professor of Medicine, Jefferson Morris Gill Professor of Cardiology, Chief, Division of Cardiovascular Medicine, University of Kentucky; Vice Chairman of Internal Medicine, Chandler Medical Center; Medical Director, Gill Heart Institute

David J Moliterno, MD is a member of the following medical societies: American College of Cardiology, American College of Physicians, American Heart Association, American Medical Association, Association of Professors of Cardiology, and European Society of Cardiology

Disclosure: Nothing to disclose.

George A Stouffer III, MD  Henry A Foscue Distinguished Professor of Medicine and Cardiology, Director of Interventional Cardiology, Cardiac Catheterization Laboratory, Chief of Clinical Cardiology, Division of Cardiology, University of North Carolina Medical Center

George A Stouffer III, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Cardiology, American College of Physicians, American Heart Association, Phi Beta Kappa, and Society for Cardiac Angiography and Interventions

Disclosure: Nothing to disclose.

Josh W Todd, MD  Fellow in Interventional Cardiology, University of North Carolina at Chapel Hill

Josh W Todd, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Cardiology, American College of Physicians, and American Heart Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Justin D Pearlman, MD, ME, PhD, FACC, MA  Chief, Division of Cardiology, Director of Cardiology Consultative Service, Director of Cardiology Clinic Service, Director of Cardiology Non-Invasive Laboratory, Director of Cardiology Quality Program KMC, Dartmouth-Hitchcock Medical Center, Dartmouth Medical School

Justin D Pearlman, MD, ME, PhD, FACC, MA is a member of the following medical societies: American College of Cardiology, American College of Physicians, American Federation for Medical Research, International Society for Magnetic Resonance in Medicine, and Radiological Society of North America

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Karlheinz Peter, MD, PhD  Professor of Medicine, Monash University; Head of Centre of Thrombosis and Myocardial Infarction, Head of Division of Atherothrombosis and Vascular Biology, Associate Director, Baker Heart Research Institute; Interventional Cardiologist, The Alfred Hospital, Australia

Karlheinz Peter, MD, PhD is a member of the following medical societies: American Heart Association, Cardiac Society of Australia and New Zealand, and German Cardiac Society

Disclosure: Nothing to disclose.

Chief Editor

Eric H Yang, MD  Associate Professor of Medicine, Director of Interventional Cardiology Fellowship Program, Henry Ford Hospital

Eric H Yang, MD is a member of the following medical societies: Alpha Omega Alpha

Disclosure: Nothing to disclose.

Additional Contributors

The authors and editors of eMedicine gratefully acknowledge the contributions of previous authors Steven James Filby, MD, Robert Vincent Kelly, MD, Jeb Burchenal, MD, James Maddux, MD, and Jorge Davalos, MD, to the development and writing of the source articles.

References
  1. Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. Jan 20 2011;364(3):226-35. [Medline].

  2. Ong P, Athanasiadis A, Hill S, Vogelsberg H, Voehringer M, Sechtem U. Coronary artery spasm as a frequent cause of acute coronary syndrome: The CASPAR (Coronary Artery Spasm in Patients With Acute Coronary Syndrome) Study. J Am Coll Cardiol. Aug 12 2008;52(7):523-7. [Medline].

  3. Scirica BM, Moliterno DJ, Every NR, Anderson HV, Aguirre FV, Granger CB, et al. Differences between men and women in the management of unstable angina pectoris (The GUARANTEE Registry). The GUARANTEE Investigators. Am J Cardiol. Nov 15 1999;84(10):1145-50. [Medline].

  4. GRACE, Global Registry of Acute Coronary Events. Available at http://www.outcomes-umassmed.org/grace/. Accessed September 16, 2010.

  5. Lupón J, Valle V, Marrugat J, Elosua R, Serés L, Pavesi M, et al. Six-month outcome in unstable angina patients without previous myocardial infarction according to the use of tertiary cardiologic resources. RESCATE Investigators. Recursos Empleados en el Síndrome Coronario Agudo y Tiempos de Espera. J Am Coll Cardiol. Dec 1999;34(7):1947-53. [Medline].

  6. Than M, Cullen L, Reid CM, Lim SH, Aldous S, Ardagh MW, et al. A 2-h diagnostic protocol to assess patients with chest pain symptoms in the Asia-Pacific region (ASPECT): a prospective observational validation study. Lancet. Mar 26 2011;377(9771):1077-84. [Medline].

  7. Misra D, Leibowitz K, Gowda RM, Shapiro M, Khan IA. Role of N-acetylcysteine in prevention of contrast-induced nephropathy after cardiovascular procedures: a meta-analysis. Clin Cardiol. Nov 2004;27(11):607-10. [Medline].

  8. de Zwaan C, Bar FW, Wellens HJ. Characteristic electrocardiographic pattern indicating a critical stenosis high in left anterior descending coronary artery in patients admitted because of impending myocardial infarction. Am Heart J. Apr 1982;;103(4 Pt 2):730-6. [Medline].

  9. Nisbet BC, Zlupko G. Repeat Wellens' syndrome: case report of critical proximal left anterior descending artery restenosis. J Emerg Med. Sep 2010;39(3):305-8. [Medline].

  10. Kwong RY, Chan AK, Brown KA, et al. Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease. Circulation. Jun 13 2006;113(23):2733-43. [Medline].

  11. Kwong RY, Sattar H, Wu H, et al. Incidence and prognostic implication of unrecognized myocardial scar characterized by cardiac magnetic resonance in diabetic patients without clinical evidence of myocardial infarction. Circulation. Sep 2 2008;118(10):1011-20. [Medline]. [Full Text].

  12. [Guideline] Wright RS, Anderson JL, Adams CD, Bridges CR, Casey DE Jr, Ettinger SM, et al. 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. Mar 28 2011;[Medline].

  13. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. Aug 16 2001;345(7):494-502. [Medline].

  14. Peters RJ, Mehta SR, Fox KA, Zhao F, Lewis BS, Kopecky SL, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation. Oct 7 2003;108(14):1682-7. [Medline].

  15. Kastrati A, Neumann FJ, Schulz S, et al. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. N Engl J Med. Nov 24 2011;365(21):1980-9. [Medline].

  16. Théroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med. Jul 16 1992;327(3):141-5. [Medline].

  17. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. Apr 4 2001;285(13):1711-8. [Medline].

  18. Murphy SA, Cannon CP, Wiviott SD, McCabe CH, Braunwald E. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial. J Am Coll Cardiol. Dec 15 2009;54(25):2358-62. [Medline].

  19. Anderson HV, Cannon CP, Stone PH, Williams DO, McCabe CH, Knatterud GL, et al. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction. J Am Coll Cardiol. Dec 1995;26(7):1643-50. [Medline].

  20. Boden WE, O'Rourke RA, Crawford MH, Blaustein AS, Deedwania PC, Zoble RG. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. N Engl J Med. Jun 18 1998;338(25):1785-92. [Medline].

  21. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet. Aug 28 1999;354(9180):708-15. [Medline].

  22. [Guideline] Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation. Aug 14 2007;116(7):e148-304. [Medline].

  23. [Guideline] American Diabetes Association. Standards of medical care in diabetes--2010. Diabetes Care. Jan 2010;33 Suppl 1:S11-61. [Medline]. [Full Text].

  24. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. Nov 16 1996;348(9038):1329-39. [Medline].

Previous
Next
 
Pathogenesis of acute coronary syndromes.
Thrombolysis in Myocardial Infarction (TIMI) Risk Score correlates with major adverse outcome and the effect of therapy with low molecular weight heparin.
Algorithm for Initial Invasive Strategy (Adapted from 2007 ACC/AHA UA/NSTEMI Guidelines).
Algorithm for Initial Conservative Strategy (Adapted from 2007 ACC/AHA UA/NSTEMI Guidelines).
Rate and timing of revascularization for patients with unstable angina using an invasive versus a conservative approach (Fragmin during instability in coronary artery disease [FRISC II]).
Time course of elevations of serum markers after acute myocardial infarction.
Table 1. Patient Characteristics, GUARANTEE Versus CRUSADE
GUARANTEE, 1995-96CRUSADE, 2001-06
Mean age62 years69 years
Patients older than 65 years44%
Female39%40%
Hypertension60%73%
Diabetes mellitus26%33%
Current smoker25%
Hypercholesterolemia43%50%
Previous stroke9%
Previous myocardial infarction36%30%
Previous angina66%
Congestive heart failure14%18%
Previous coronary intervention23%21%
Previous coronary bypass surgery25%19%
Table 2. Demographic Characteristics of Patients in the International OASIS-2 Registry
CharacteristicsAustraliaBrazilCanadaHungaryPolandUnited States
GeneralNumber of patients1899147816269311135918
Mean age (y)656266656366
Women (%)374237454037
ClinicalNQMI presentation (%)7714221716
Abnormal electrocardiogram (ECG)( %)749182959787
Select treatmentsBeta-blocker (%)675373675957
Calcium blocker (%)595153524359
Invasive procedures (index hospitalization)Cardiac catheterization (%)24694320758
Percutaneous coronary intervention (PCI) (%)7191650.424
Coronary artery bypass graft (CABG) (%)4201070.417
Table 3. Thirty-Day Clinical Outcome in Patients With Acute Coronary Syndromes in Clinical Trials
StudyYearNumber of PatientsDeath (%)Myocardial infarction (%)Major Bleed (%)
TIMI-3*19941,4732.59.00.3
GUSTO-IIb † 19978,0113.86.01.0
ESSENCE ‡ 19983,1713.34.51.1
PARAGON-A § 19982,2823.210.34.0
PRISM || 19983,2323.04.20.4
PRISM-PLUS ¶ 19981,9154.48.11.1
PURSUIT#199810,9483.612.92.1
TIMI-11B**19993,9103.96.01.3
PARAGON-B †† 20005,2253.19.31.1
Pooled40,1673.58.51.5
* TIMI-3: Thrombolysis in Myocardial Infarction Clinical Trial 3



† GUSTO-IIb: Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries.



‡ ESSENCE: Efficacy and Safety of Subcutaneous Enoxaparin in Non–Q-wave Coronary Events.



§ PARAGON-A: Platelet IIb/IIIa Antagonism (lamifiban) for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network.



|| PRISM: Platelet Receptor Inhibition in Ischemic Syndrome Management.



¶ PRISM-PLUS: Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Angina Signs and Symptoms.



# PURSUIT: Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy.



** TIMI-11B: Thrombolysis in Myocardial Infarction Clinical Trial 11B.



†† PARAGON-B: Platelet IIb/IIIa Antagonism (lamifiban) for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network



Table 4. Braunwald Classification of Unstable Angina
CharacteristicClass/CategoryDetails
SeverityISymptoms with exertion
IISubacute symptoms at rest (2-30 d prior)
IIIAcute symptoms at rest (within prior 48 h)
Clinical precipitating factorASecondary
BPrimary
CPostinfarction
Therapy during symptoms1No treatment
2Usual angina therapy
3Maximal therapy
Table 5. AHA/ACC Recommendations for a Preferred Invasive Strategy
Preferred StrategyPatient Characteristics
InvasiveRecurrent angina/ischemia at rest or with low-level activities despite intensive medical therapy
Elevated cardiac biomarkers (TnT or TnI)
New or presumably new ST-segment depression
Signs or symptoms of heart failure or new or worsening mitral regurgitation
High-risk findings on noninvasive stress testing
High-risk score (eg, TIMI, GRACE)
Reduced LV systolic function (LVEF less than 40%)
Hemodynamic instability
Sustained ventricular tachycardia
PCI within 6 months
Previous CABG
ConservativeLow-risk score (eg, TIMI, GRACE)
Patient or physician preference in the absence of high-risk features
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.